EXELTIS is aware that the security of your private information from the use of our site (the "Site") is an important concern. With this privacy statement, we would like to inform you about our security measures.

EXELTIS will not collect any personally identifiable information about you (ie, your name, address, telephone number, or email address) unless you provide it to EXELTIS voluntarily. You can use many features of the EXELTIS site without disclosing your personal data. You are not required to provide any personal information as a condition of using our Site, except as may be necessary to provide you a product or service at your request.

EXELTIS collects personal data only when you provide it to us, through registration, through completion of forms or emails, as part of an order for products or services, through inquiries or requests about materials being ordered, and similar situations in which you have chosen to provide the information to EXELTIS.

When you do provide EXELTIS with personally identifiable information, we may use that information in the following ways, unless stated otherwise: we may store and process that information to better understand your needs and how we can improve our products and services; we may use that information to contact you; and we may provide that information to third parties in connection with referrals, recommendations, or references as otherwise described herein.

The personal data you disclose to us remains at EXELTIS and/or with data processors or servers acting on our behalf and responsible to us. We may disclose the personal data we collect to third-party service providers in connection with services that they perform for us, such as running and fulfilling promotions, conducting surveys, and email and direct mail delivery services. Your personal data will not otherwise be passed on by us or by our agents for use by third parties in any form whatsoever unless we have obtained your consent; are legally required to do so such as to comply with the law or a legal request such as a subpoena to protect the company's rights, property, or interests; or in the event of a sale of assets or other corporate restructuring.

In light of the importance of protecting children's privacy, we do not collect, process, or use on our Site any information relating to an individual whom we know to be under 13 years old without the prior, verifiable consent of his or her legal representative. Such legal representative has the right, upon request, to view the information provided by the child and/or to require that it be deleted.

In some cases, EXELTIS may collect information about you that is not personally identifiable. Examples of this type of information include the type of Internet browser you are using, the type of computer operating system you are using, and the domain name or IP address of the site from which you linked to our Site.

This Site may use cookies to record user-specific information on what pages users access or visit, record past activity at a site in order to provide better service when visitors return to our site, and gather statistical information to help improve user experience. With most Internet browsers, you can erase cookies from your computer hard drive, block all cookies, or receive a warning before a cookie is stored. Please refer to your browser instructions to learn more about these functions.

If you have submitted personally identifiable information through the EXELTIS site and would like that information deleted from our records, please contact us at contactusUSA@exeltis.com and provide us with the requested information. We will use reasonable efforts to delete this information from our existing files.

If you would like to communicate with us or have questions, comments, or complaints about this Policy, or the Site, please forward such communication to contactusUSA@exeltis.com.

The constant development of the Internet requires occasional adjustments to our privacy statement. EXELTIS retains the right to make changes when necessary and will communicate any updates promptly on this page. Please check back periodically.

INDICATIONS AND USAGE

Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.

This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

Contraindications

Benznidazole Tablets are contraindicated in patients with a history of hypersensitivity reactions to benznidazole or other nitroimidazole derivatives. Reactions have included severe skin and soft tissue reactions. Benznidazole Tablets is also contraindicated in patients who have taken disulfiram within the last two weeks. Psychotic reactions may occur in patients who are using benznidazole and disulfiram concurrently. Consumption of alcoholic beverages or products containing propylene glycol is contraindicated in patients during and for at least 3 days after therapy with Benznidazole Tablets. A disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) may occur due to the interaction between alcohol or propylene glycol and benznidazole. Benznidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to benznidazole in patients with Cockayne syndrome.

Warnings and Precautions

Potential for Genotoxicity and Carcinogenicity: Genotoxicity has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents. A study evaluating the cytogenetic effect of benznidazole in pediatric patients ranging from 11 months to 11 years of age (the safety and effectiveness of Benznidazole Tablets in patients less than 2 years old has not been established) with Chagas disease demonstrated a two-fold increase in chromosomal aberrations. In pediatric patients with Chagas disease who were treated with benznidazole, the median incidence of micronucleated interphase lymphocytes in 20 patients increased two-fold compared to pre-dose values. In the same study, the mean incidence of chromosomal aberrations in 10 patients also increased two-fold compared to pre-dose values.

Carcinogenicity has been observed in mice and rats treated chronically with nitroimidazole agents, which are structurally similar to benznidazole. Similar data have not been reported for benznidazole. It is not known whether benznidazole is associated with carcinogenicity in humans.

Embryo-Fetal Toxicity: Based on animal studies, Benznidazole Tablets can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Pregnancy testing is recommended for women of reproductive potential prior to Benznidazole Tablets therapy. Advise women of reproductive potential to use effective contraception during treatment with Benznidazole Tablets and for 5 days after the last dose.

Hypersensitivity Skin Reactions: Serious skin and subcutaneous disorders, including acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), erythema multiforme, and eosinophilic drug reactions, have been reported with benznidazole. Discontinue treatment at first evidence of these serious cutaneous reactions. Extensive skin reactions, such as rashes, have also been reported. Most cases occurred after approximately 10 days of treatment with benznidazole. Most rashes resolved with treatment discontinuation. In case of skin reactions presenting with additional symptoms or signs of systemic involvement, such as lymphadenopathy, fever, and/or purpura, discontinuation of treatment is recommended.

Central and Peripheral Nervous System Effects: Benznidazole Tablets can cause paresthesia or symptoms of peripheral neuropathy that may take several months to resolve. Headache and dizziness have been reported. In cases where neurological symptoms occur, immediate discontinuation of treatment is recommended. In most cases, symptoms occur late in the course of treatment.

Hematological Manifestations of Bone Marrow Depression: There have been reports of hematological manifestations of bone marrow depression, such as neutropenia, thrombocytopenia, anemia, and leukopenia, which resolved after treatment discontinuation. Patients with hematological manifestations of bone marrow depression must take Benznidazole Tablets only under strict medical supervision. Monitor complete blood count. Total and differential leukocyte counts are recommended before, during, and after therapy.

Adverse Reactions

The most common adverse reactions observed were abdominal pain (25%), rash (16%), decreased weight (13%), and headache (7%).

Use in Specific Populations

Lactation Risk: Limited published literature based on breast milk sampling reports that benznidazole is present in human milk. There are no reports of adverse effects on the breastfed infant and no information on the effects of benznidazole on milk production. Because of the potential for serious adverse reactions, and transmission of Chagas disease, advise patients that breastfeeding is not recommended during treatment with Benznidazole Tablets.

Male Infertility: Based on findings in rodents, Benznidazole Tablets may impair fertility in males of reproductive potential. It is not known whether effects on fertility are reversible.

Before prescribing Benznidazole Tablets and for further safety information, please read the full Prescribing Information here.

Indications and Usage and Important Safety Information

INDICATIONS AND USAGE

Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.

This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.